World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
85
Citations
38397
World Ranking
1298
National Ranking
675

Medicine

D-Index
85
Citations
38471
World Ranking
14394
National Ranking
7279

Overview

Neil M.H. Graham is affiliated with Regeneron in the United States and has contributed extensively to the field of medicine. Their research primarily spans multiple subfields including physiology, dermatology, immunology and allergy, immunology, and surgery. The bulk of their work focuses on asthma and respiratory diseases, dermatology and skin diseases, and allergic rhinitis and sensitization. Additional research topics include IL-33, ST2, and ILC pathways, eosinophilic esophagitis, sinusitis and nasal conditions, and food allergy and anaphylaxis research.

Their recent scholarly output includes significant publications across well-established journals with a focus on atopic and allergic diseases. Notable papers include:

  • Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial, 2020, Journal of the American Academy of Dermatology
  • Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases, 2021, Clinical & Experimental Allergy
  • Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis, 2021, The Lancet Respiratory Medicine
  • Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis, 2020, American Journal of Clinical Dermatology
  • Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS, 2020, Journal of the American Academy of Dermatology

Neil M.H. Graham frequently collaborates with other researchers in the field. Their most common coauthors include:

  • Naimish Patel
  • Marcella Ruddy
  • Marius Ardeleanu
  • Gianluca Pirozzi
  • Megan S. Rice

Their work is published across several recurring venues, including:

  • British Journal of Dermatology
  • Journal of the American Academy of Dermatology
  • The Journal of Allergy and Clinical Immunology In Practice
  • American Journal of Clinical Dermatology
  • Annals of Allergy Asthma & Immunology

In addition to journal publications, Neil M.H. Graham has contributed to the book titled Infectious Disease Epidemiology: Theory and Practice published by Ministerio de Defensa in 2022.

Best Publications

  • Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

    Eric L. Simpson;Thomas Bieber;Emma Guttman-Yassky;Lisa A. Beck

  • Epidemiology and Estimated Population Burden of Selected Autoimmune Diseases in the United States

    Denise L. Jacobson;Stephen J. Gange;Noel R. Rose;Neil M.H. Graham

  • Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

    Mario Castro;Jonathan Corren;Ian D. Pavord;Jorge Maspero

  • Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.

    Lisa A. Beck;Diamant Thaçi;Jennifer D. Hamilton;Neil M. Graham

  • Dupilumab in persistent asthma with elevated eosinophil levels.

    Sally Wenzel;Linda Ford;David Pearlman;Sheldon Spector

  • Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

    Claus Bachert;Claus Bachert;Joseph K Han;Martin Desrosiers;Peter W Hellings

  • Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

    Andrew Blauvelt;Marjolein de Bruin-Weller;Melinda Gooderham;Jennifer C. Cather

  • Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.

    Klaus F. Rabe;Parameswaran Nair;Guy Brusselle;Jorge F. Maspero

  • Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

    Sally Wenzel;Mario Castro;Jonathan Corren;Jorge Maspero

  • Dementia in AIDS patients: Incidence and risk factors

    J. C. McArthur;D. R. Hoover;H. Bacellar;E. N. Miller

  • Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial

    Claus Bachert;Claus Bachert;Leda Mannent;Robert M Naclerio;Joaquim Mullol

  • Targeting key proximal drivers of type 2 inflammation in disease

    Namita A. Gandhi;Brandy L. Bennett;Neil M. H. Graham;Gianluca Pirozzi

  • Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.

    Diamant Thaçi;Eric L Simpson;Lisa A Beck;Thomas Bieber

  • Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation.

    Delia Goletti;Drew Weissman;Robert W. Jackson;Neil M.H. Graham

  • Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis

    Emma Guttman-Yassky;Emma Guttman-Yassky;Robert Bissonnette;Benjamin Ungar;Benjamin Ungar;Mayte Suárez-Fariñas

  • Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.

    Eric L. Simpson;Amy S. Paller;Elaine C. Siegfried;Mark Boguniewicz

  • Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)

    M. de Bruin-Weller;D. Thaçi;C.H. Smith;K. Reich

  • Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.

    Jennifer D. Hamilton;Mayte Suárez-Fariñas;Nikhil Dhingra;Irma Cardinale

  • Potential factors affecting adherence with HIV therapy

    Supriya Mehta;Richard D. Moore;Neil M. H. Graham

  • Commonality of the IL-4/IL-13 pathway in atopic diseases

    Namita A. Gandhi;Gianluca Pirozzi;Neil M. H. Graham

Frequent Co-Authors

Gianluca Pirozzi
Gianluca Pirozzi Sanofi (France)
David Vlahov
David Vlahov Yale University
Claus Bachert
Claus Bachert Karolinska Institute
Jonathan Corren
Jonathan Corren University of California, Los Angeles
George D. Yancopoulos
George D. Yancopoulos Regeneron (United States)
Alfred J. Saah
Alfred J. Saah MSD (United States)
Mario Castro
Mario Castro Washington University in St. Louis
Emma Guttman-Yassky
Emma Guttman-Yassky Icahn School of Medicine at Mount Sinai
Donald R. Hoover
Donald R. Hoover Rutgers, The State University of New Jersey
Ian D. Pavord
Ian D. Pavord University of Oxford

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in expanding their knowledge of Immunology or pursuing a healthcare career related to the immune system, several online degree options offer flexible and accessible pathways. Programs such as the fastest and easiest lpn programs provide a quick entry point into nursing, perfect for building foundational clinical skills.

Nursing professionals aiming for advanced practice roles might consider nurse practitioner programs with easy admission. These programs often balance accessibility with quality education, enabling students to move forward efficiently.

Specializing further, psychiatric mental health nurse practitioner (PMHNP) programs play a crucial role in mental health care, with some offering exceptional practical training opportunities. The best pmhnp programs are noted for their strong clinical placement rates, ensuring graduates are well-prepared for real-world practice.

Cost is also a significant factor, and prospective students can explore the cheapest online pmhnp programs to find affordable options without compromising educational quality. These pathways collectively support diverse career trajectories linked to immunology and nursing.

Best Scientists Citing Neil M.H. Graham

Trending Scientists

Recently Published Articles